Jefferies Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-15,000
Closed -$186K 1542
2022
Q1
$186K Buy
+15,000
New +$232K ﹤0.01% 1278
2020
Q2
Sell
-135,000
Closed -$1.96M 1314
2020
Q1
$1.96M Sell
135,000
-31,500
-19% -$556K 0.02% 699
2019
Q4
$3.37M Buy
+166,500
New +$1.53M 0.03% 741

Other funds holding AUPH

Jefferies Group's AUPH Position: Q1 2022 in Review

Jefferies Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 4,550 shares — an estimated $70.3K sold.

Jefferies Group first reported a position in AUPH in Q4 2019 and held it in 3 quarters. The position peaked at $122K in Q4 2019. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Jefferies Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 4,550 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $70.3K.
  • Jefferies Group first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Jefferies Group's Aurinia Pharmaceuticals position peaked at $122K in Q4 2019.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.